Full Breakdown
Trump Administration's Policy on Transgender Hormone Therapy in Federal Prisons
3/10/2026, 9:57:21 PM
Overview of the Policy Change
On February 19, 2025, the Federal Bureau of Prisons (BOP) issued guidance mandating a tapering of hormone therapy for incarcerated transgender individuals diagnosed with gender dysphoria. This directive follows an executive order from President Donald Trump that prohibits federal funds from being allocated for medical treatments aimed at aligning physical characteristics with an individual's gender identity.
Medical Concerns and Implications
Medical professionals have expressed significant concern regarding the implications of this policy. Dr. Carl Streed, a primary-care physician and researcher in transgender health, stated that discontinuing hormone therapy could lead to immediate cognitive and mood changes, as well as long-term health risks such as cardiovascular disease and metabolic disorders. He emphasized that the policy contradicts established medical practices and could exacerbate health disparities for incarcerated transgender individuals, who are already at a higher risk for violence and inadequate healthcare.
Ethical Considerations and Criticism
The principle of non-maleficence, or "do no harm," is a cornerstone of medical ethics, and critics argue that the new policy directly violates this tenet. Advocacy groups, including Just Detention International, have condemned the guidance as an act of "overt bigotry" that places transgender individuals in federal custody at greater risk of abuse and neglect. Jesse Lerner-Kinglake, the communications director at Just Detention International, noted that removing gender-affirming care sends a clear message about the lack of concern for the safety and dignity of incarcerated transgender people.
Legal Challenges and Ongoing Litigation
The policy has sparked legal challenges, notably the case Kingdom v. Trump, filed by three transgender individuals in federal prisons who had been receiving hormone therapy. The American Civil Liberties Union and the Transgender Law Center are representing these individuals, arguing that the new guidance violates a preliminary injunction requiring the BOP to continue hormone therapy for those diagnosed with gender dysphoria. Shayna Medley, a senior litigation staff attorney at Advocates for Trans Equality, stated that the BOP's new directive is in direct conflict with the court's order.
Conclusion and Future Implications
As the legal battle unfolds, the BOP's decision to taper hormone therapy raises critical questions about the treatment of transgender individuals in federal custody. With approximately 150,000 individuals housed in federal prisons, the potential health consequences of this policy could be profound. Dr. Streed warned that withdrawing hormone therapy poses significant dangers, underscoring the urgent need for a reevaluation of how the federal prison system addresses the healthcare needs of transgender inmates.
Verbatim Quotes
- “And this is going to have direct harm on people.” — Dr. Carl Streed, Primary-Care Physician
- “The devastating health effects of discontinuing hormone therapy for incarcerated transgender people are well-documented,” — Jesse Lerner-Kinglake, Communications Director, Just Detention International
- “Our view is that this guidance is currently enjoined by the existing injunction in the Kingdom v. Trump litigation,” — Shayna Medley, Senior Litigation Staff Attorney, Advocates for Trans Equality
Conflicting Reports & Gaps
While the BOP's new guidance has been met with widespread criticism, the Bureau has not publicly commented on the matter. The ongoing litigation may further clarify the legal standing of the policy and its implications for the treatment of transgender individuals in federal custody.
